## LH: Labcorp Holdings Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.1% below STRENGTH zone (3.0-6.0%); PEG 1.94 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($252.55)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Is the Options Market Predicting a Spike in Labcorp Holdings Stock?**
- Source: TradingView â€” Track All Markets | 20251215T140849 | Somewhat-Bearish | Relevance: 100%
- The options market is showing a high implied volatility for Labcorp Holdings (LH) stock, particularly with the Feb 20, 2026 $135 Call. This suggests investors anticipate a significant price movement, possibly due to an upcoming event. Despite this, analysts currently rate Labcorp Holdings as a Zacks Rank #3 (Hold), with recent downward revisions to earnings estimates.

**2. Labcorp (LH): Reassessing Valuation After Reduced Growth Outlook for Contract Research Unit**
- Source: Simply Wall Street | 20251213T190811 | Neutral | Relevance: 100%
- Labcorp Holdings (LH) recently beat earnings expectations but has seen its stock react negatively due to management's cautious tone and reduced revenue growth targets for its contract research unit. Despite a long-term solid performance, the company faces reassessment by investors considering slower growth in a key unit. While analysts suggest it's undervalued with a fair value of $299.71, concerns about policy shifts and regulatory pressure could impact margins.

**3. Labcorp (LH): Reassessing Valuation After Reduced Growth Outlook for Contract Research Unit**
- Source: Simply Wall Street | 20251213T185008 | Somewhat-Bearish | Relevance: 100%
- Labcorp Holdings (LH) recently surpassed earnings expectations but saw its stock react negatively due to management's cautious outlook, including reduced revenue growth targets for its contract research unit and a trimmed full-year forecast. Despite a strong 5-year shareholder return, the stock's recent weakness suggests investors are reassessing growth risks. Analysts currently see Labcorp as undervalued with a fair value of $299.71, though its P/E ratio is higher than the broader US healthcare sector.

**4. LabCorp Holdings Inc. (LH) Files Form 8-K with SEC**
- Source: GuruFocus | 20251216T012500 | Neutral | Relevance: 100%
- LabCorp Holdings Inc. (LH) has filed a Form 8-K with the SEC on December 9, 2025, to disclose significant company developments. Although specific details of the filing were not provided in this release, such reports typically announce material events like mergers, leadership changes, or other financial or operational impacts. Investors are encouraged to review the full document on the SEC's website for complete information.

**5. Cofactor Genomics, Inc. announced that it has received funding from Labcorp Holdings Inc., Ascension Ventures, LLC**
- Source: marketscreener.com | 20251215T190838 | Somewhat-Bullish | Relevance: 100%
- Cofactor Genomics, Inc. has secured a new round of funding on December 15, 2025. The investment saw participation from new investor Labcorp Holdings Inc. and existing investor Ascension Ventures, LLC. As part of the transaction, Cofactor Genomics issued convertible preferred shares.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 5 ($3.37M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-0.7%)
- Blackrock Inc.: 9.8% (-10.3%)
- State Street Corpora: 4.6% (-0.8%)
- Victory Capital Mana: 3.2% (+20.0%)
- JPMORGAN CHASE & CO: 2.6% (+64.8%)

### Key Risks

1. Insider selling cluster: $3.4M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_10 improving +5.2% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.94 elevated, pricing in significant growth expectations. Forward P/E 15.0x stretched relative to 7% growth. Insider selling cluster ($3.4M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $21.9B |
| Beta | 0.96 |
| 52W Range | $209.38 - $293.72 |
| Short Interest | 4.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.94 |
| Forward P/E | 15.0 |
| Current P/E | 16.1 |
| YoY Growth | 7.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -3.1% to 2.1% (+5.2% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.9pp (needs >3.0% for momentum thesis). MRS_5 at 1.9% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.02x) but short-term weakness (below SMA20). RSI neutral at 49. OFD pattern: -MLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.09% (CS: 50) | Neutral |
| RSI_14 | 48.8 | Neutral |
| MACD Histogram | 0.21 | Bullish |
| vs SMA20 | 0.999x | Below |
| vs SMA50 | 0.985x | Below |
| vs SMA200 | 1.023x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $263.33
- **Stop Loss:** $252.55 (4.1% risk)
- **Target:** $274.11 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 111
- **Position Value:** $29,229.63
- **Portfolio %:** 29.23%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-05 (Est: $3.94)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.14 | $4.18 | +1.0% |
| 2025Q2 | $4.18 | $4.35 | +4.1% |
| 2025Q1 | $3.73 | $3.84 | +2.8% |
| 2024Q4 | $3.39 | $3.45 | +1.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*